Expression of RAGE-1 gene in acute myeloid leukemia.
10.7534/j.issn.1009-2137.2013.01.005
- Author:
Hai-Yan CHAI
1
;
Jun QIAN
;
Jiang LIN
;
Jing YANG
;
Yun LI
;
Cui-Zhu WANG
;
Xing-Xing CHEN
;
Qin CHEN
;
Zhao-Qun DENG
;
Dong-Ming YAO
;
Ji-Chun MA
Author Information
1. Shanxi Medical University First Clinical Hospital, Taiyuan, Shanxi Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Cell Line, Tumor;
Female;
Gene Expression;
Humans;
Karyotyping;
Leukemia, Myeloid, Acute;
genetics;
Male;
Middle Aged;
Prognosis;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(1):20-24
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to detect the expression of RAGE-1 transcript in the bone marrow mononuclear cells (BMMNC) from patients with acute myeloid leukemia (AML) and to investigate the relationship of RAGE-1 expression level with clinical variables. The expression level of RAGE-1 gene in BMMNC from 94 newly diagnosed AML patients was measured using RQ-PCR. The relationship between RAGE-1 expression level and clinical parameters (age, sex, blood cell counts, diagnosis and prognosis) was investigated, and the levels of RAGE-1 expression were compared in patients before and after treatment. The results showed that overexpression of RAGE-1 transcript was found in 28% (26/94) AML patients (1.34 - 16.34, median 3.07). No significant difference was observed in sex, age, blood parameters and FAB subtypes between the groups with and without RAGE-1 overexpression. There was also no significant difference in the frequency of RAGE-1 overexpression among different cytogenetic risk groups and among the patients with different types of karyotypes. The level of RAGE-1 transcript significantly decreased in those patients obtained complete remission after treatment. The overall survival of AML patients with RAGE-1 overexpression was similar as that in those without RAGE-1 overexpression. It is concluded that RAGE-1 overexpression is a common event in AML, but has no impact on the prognosis of patients.
